Regulus Therapeutics Revenue and Competitors

Location

$269.2M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Regulus Therapeutics's estimated annual revenue is currently $7.5M per year.(i)
  • Regulus Therapeutics's estimated revenue per employee is $182,927
  • Regulus Therapeutics's total funding is $269.2M.

Employee Data

  • Regulus Therapeutics has 41 Employees.(i)
  • Regulus Therapeutics grew their employee count by -13% last year.

Regulus Therapeutics's People

NameTitleEmail/Phone
1
CSOReveal Email/Phone
2
Chief ExecutiveReveal Email/Phone
3
Head GMP Manufacturing & SupplyReveal Email/Phone
4
VP (Translational Medicine)Reveal Email/Phone
5
VP CMCReveal Email/Phone
6
VP, BiologyReveal Email/Phone
7
VP, Business DevelopmentReveal Email/Phone
8
SVP and General CounselReveal Email/Phone
9
SVP Clinical OperationsReveal Email/Phone
10
VP Chemistry & Pharmaceutical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Regulus Therapeutics?

Regulus Therapeutics is a biopharmaceutical company created to discover, develop and commercialize microRNA therapeutics. Formed as a joint venture between Isis – a pioneer in oligonucleotide drug technologies and a leader in the field of antisense therapeutics, and Alnylam – a leader in the field of RNAi therapeutics, Regulus intends to address therapeutic opportunities that arise from abnormal expression or mutations in microRNAs. Since microRNAs regulate the expression of broad networks of genes and biological pathways, microRNA therapeutics define a new strategy to target multiple points on disease pathways. Regulus has assembled world-class scientists and the foremost authorities in the field of microRNA research to lead this new venture. In addition, Regulus has been formed combining the leading capabilities and intellectual property estates of its two parent companies. Thus, in Regulus, its founders have created the leading microRNA therapeutics company, a company that will translate one of the most important new frontiers in modern biology into an entirely new approach for innovative medicines by targeting the pathways of human disease with microRNA therapeutics.

keywords:N/A

$269.2M

Total Funding

41

Number of Employees

$7.5M

Revenue (est)

-13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Regulus Therapeutics News

2022-04-20 - Regulus Therapeutics (NASDAQ:RGLS) Now Covered by ...

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs...

2022-04-13 - Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated at ...

HC Wainwright restated a “buy” rating and set a $2.00 price objective on shares of Regulus Therapeutics in a research note on Tuesday, January...

2022-03-22 - Regulus Therapeutics Announces Initiation of Preclinical ...

Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines...

2021-08-10 - Regulus Therapeutics Reports Second Quarter 2021 Financial Results and Recent Updates

SAN DIEGO, Aug. 10, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the second quarter ended June 3 ...

2021-08-03 - Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference Call

SAN DIEGO, Aug, 3, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report financial results and highlights ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.1M41-18%N/A
#2
$4.8M418%N/A
#3
$3.2M41-35%$39.4M
#4
$8.9M413%N/A
#5
$6.7M413%N/A